Cargando…

Probiotics for the treatment of depression and its comorbidities: A systemic review

Depression is one of the most common psychiatric conditions, characterized by significant and persistent depressed mood and diminished interest, and often coexists with various comorbidities. The underlying mechanism of depression remain elusive, evidenced by the lack of an appreciate therapy. Recen...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Jie, Zhao, Longyou, Cheng, Yiwen, Lei, Wenhui, Wang, Yu, Liu, Xia, Zheng, Nengneng, Shao, Li, Chen, Xulei, Sun, Yilai, Ling, Zongxin, Xu, Weijie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10149938/
https://www.ncbi.nlm.nih.gov/pubmed/37139495
http://dx.doi.org/10.3389/fcimb.2023.1167116
_version_ 1785035255064821760
author Gao, Jie
Zhao, Longyou
Cheng, Yiwen
Lei, Wenhui
Wang, Yu
Liu, Xia
Zheng, Nengneng
Shao, Li
Chen, Xulei
Sun, Yilai
Ling, Zongxin
Xu, Weijie
author_facet Gao, Jie
Zhao, Longyou
Cheng, Yiwen
Lei, Wenhui
Wang, Yu
Liu, Xia
Zheng, Nengneng
Shao, Li
Chen, Xulei
Sun, Yilai
Ling, Zongxin
Xu, Weijie
author_sort Gao, Jie
collection PubMed
description Depression is one of the most common psychiatric conditions, characterized by significant and persistent depressed mood and diminished interest, and often coexists with various comorbidities. The underlying mechanism of depression remain elusive, evidenced by the lack of an appreciate therapy. Recent abundant clinical trials and animal studies support the new notion that the gut microbiota has emerged as a novel actor in the pathophysiology of depression, which partakes in bidirectional communication between the gut and the brain through the neuroendocrine, nervous, and immune signaling pathways, collectively known as the microbiota-gut-brain (MGB) axis. Alterations in the gut microbiota can trigger the changes in neurotransmitters, neuroinflammation, and behaviors. With the transition of human microbiome research from studying associations to investigating mechanistic causality, the MGB axis has emerged as a novel therapeutic target in depression and its comorbidities. These novel insights have fueled idea that targeting on the gut microbiota may open new windows for efficient treatment of depression and its comorbidities. Probiotics, live beneficial microorganisms, can be used to modulate gut dysbiosis into a new eubiosis and modify the occurrence and development of depression and its comorbidities. In present review, we summarize recent findings regarding the MGB axis in depression and discuss the potential therapeutic effects of probiotics on depression and its comorbidities.
format Online
Article
Text
id pubmed-10149938
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-101499382023-05-02 Probiotics for the treatment of depression and its comorbidities: A systemic review Gao, Jie Zhao, Longyou Cheng, Yiwen Lei, Wenhui Wang, Yu Liu, Xia Zheng, Nengneng Shao, Li Chen, Xulei Sun, Yilai Ling, Zongxin Xu, Weijie Front Cell Infect Microbiol Cellular and Infection Microbiology Depression is one of the most common psychiatric conditions, characterized by significant and persistent depressed mood and diminished interest, and often coexists with various comorbidities. The underlying mechanism of depression remain elusive, evidenced by the lack of an appreciate therapy. Recent abundant clinical trials and animal studies support the new notion that the gut microbiota has emerged as a novel actor in the pathophysiology of depression, which partakes in bidirectional communication between the gut and the brain through the neuroendocrine, nervous, and immune signaling pathways, collectively known as the microbiota-gut-brain (MGB) axis. Alterations in the gut microbiota can trigger the changes in neurotransmitters, neuroinflammation, and behaviors. With the transition of human microbiome research from studying associations to investigating mechanistic causality, the MGB axis has emerged as a novel therapeutic target in depression and its comorbidities. These novel insights have fueled idea that targeting on the gut microbiota may open new windows for efficient treatment of depression and its comorbidities. Probiotics, live beneficial microorganisms, can be used to modulate gut dysbiosis into a new eubiosis and modify the occurrence and development of depression and its comorbidities. In present review, we summarize recent findings regarding the MGB axis in depression and discuss the potential therapeutic effects of probiotics on depression and its comorbidities. Frontiers Media S.A. 2023-04-17 /pmc/articles/PMC10149938/ /pubmed/37139495 http://dx.doi.org/10.3389/fcimb.2023.1167116 Text en Copyright © 2023 Gao, Zhao, Cheng, Lei, Wang, Liu, Zheng, Shao, Chen, Sun, Ling and Xu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cellular and Infection Microbiology
Gao, Jie
Zhao, Longyou
Cheng, Yiwen
Lei, Wenhui
Wang, Yu
Liu, Xia
Zheng, Nengneng
Shao, Li
Chen, Xulei
Sun, Yilai
Ling, Zongxin
Xu, Weijie
Probiotics for the treatment of depression and its comorbidities: A systemic review
title Probiotics for the treatment of depression and its comorbidities: A systemic review
title_full Probiotics for the treatment of depression and its comorbidities: A systemic review
title_fullStr Probiotics for the treatment of depression and its comorbidities: A systemic review
title_full_unstemmed Probiotics for the treatment of depression and its comorbidities: A systemic review
title_short Probiotics for the treatment of depression and its comorbidities: A systemic review
title_sort probiotics for the treatment of depression and its comorbidities: a systemic review
topic Cellular and Infection Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10149938/
https://www.ncbi.nlm.nih.gov/pubmed/37139495
http://dx.doi.org/10.3389/fcimb.2023.1167116
work_keys_str_mv AT gaojie probioticsforthetreatmentofdepressionanditscomorbiditiesasystemicreview
AT zhaolongyou probioticsforthetreatmentofdepressionanditscomorbiditiesasystemicreview
AT chengyiwen probioticsforthetreatmentofdepressionanditscomorbiditiesasystemicreview
AT leiwenhui probioticsforthetreatmentofdepressionanditscomorbiditiesasystemicreview
AT wangyu probioticsforthetreatmentofdepressionanditscomorbiditiesasystemicreview
AT liuxia probioticsforthetreatmentofdepressionanditscomorbiditiesasystemicreview
AT zhengnengneng probioticsforthetreatmentofdepressionanditscomorbiditiesasystemicreview
AT shaoli probioticsforthetreatmentofdepressionanditscomorbiditiesasystemicreview
AT chenxulei probioticsforthetreatmentofdepressionanditscomorbiditiesasystemicreview
AT sunyilai probioticsforthetreatmentofdepressionanditscomorbiditiesasystemicreview
AT lingzongxin probioticsforthetreatmentofdepressionanditscomorbiditiesasystemicreview
AT xuweijie probioticsforthetreatmentofdepressionanditscomorbiditiesasystemicreview